98 results match your criteria: "Centre de protontherapie d'Orsay[Affiliation]"

A multidisciplinary view of flash irradiation.

Cancer Radiother

October 2024

Institut Curie, Research Division, Inserm U 1021-CNRS UMR 3347, université Paris-Saclay, université PSL, centre universitaire, 91401 Orsay cedex, France. Electronic address:

The delivery of ultra-high dose rates of radiation, called flash irradiation or flash-RT, has emerged as a new modality of radiotherapy shaking up the paradigm of proportionality of effect and dose whatever the method of delivery of the radiation. The hallmark of flash-RT is healthy tissue sparing from the side effects of radiation without decrease of the antitumor efficiency in animal models. In this review we will define its specificities, the molecular mechanisms underlying the flash effect and the ongoing developments to bring this new modality to patient treatment.

View Article and Find Full Text PDF

Long-term weight gain in children with craniopharyngioma.

Eur J Endocrinol

May 2024

Paediatric Endocrinology, Diabetology, Gynaecology Department, Necker-Enfants Malades University Hospital, AP-HP Centre, Paris 75015, France.

Objective: Adamantinomatous craniopharyngioma mainly affects children. Excessive weight gain is a major long-term complication. The primary objective of this study was to assess long-term weight changes in children treated for craniopharyngioma.

View Article and Find Full Text PDF

Thoracic Proton Minibeam Radiation Therapy: Tissue Preservation and Survival Advantage Over Conventional Proton Therapy.

Int J Radiat Oncol Biol Phys

October 2024

Institut Curie, Université PSL, CNRS UMR3347, INSERM U1021, Signalisation Radiobiologie et Cancer, Orsay, France; Université Paris-Saclay, CNRS UMR3347, INSERM U1021, Signalisation Radiobiologie et Cancer, Orsay, France. Electronic address:

Purpose: Proton minibeam radiation therapy (pMBRT) is an innovative radiation therapy approach that highly modulates the spatial dimension of the dose delivery using narrow, parallel, and submillimetric proton beamlets. pMBRT has proven its remarkable healthy tissue preservation in the brain and skin. This study assesses the potential advantages of pMBRT for thoracic irradiations compared with conventional radiation therapy in terms of normal tissue toxicity.

View Article and Find Full Text PDF

GH and Childhood-onset Craniopharyngioma: When to Initiate GH Replacement Therapy?

J Clin Endocrinol Metab

July 2023

Paediatric Endocrinology, Diabetology, Gynaecology Department, Necker-Enfants Malades University Hospital, AP-HP Centre, 75015 Paris, France.

Article Synopsis
  • Craniopharyngioma is a benign brain tumor that often leads to GH deficiency in children, prompting the use of growth hormone replacement therapy (GHRT).
  • A study analyzed the timing of GHRT initiation post-treatment in 71 affected patients, grouping them based on whether they started treatment before or after 12 months.
  • Results showed no significant difference in the risk of tumor recurrence or progression between patients who started GHRT sooner versus those who waited longer, indicating that the timing of therapy may not impact clinical outcomes.
View Article and Find Full Text PDF

Proton minibeam radiation therapy for treating metastases: A treatment plan study.

Med Phys

April 2023

Institut Curie, Université PSL, CNRS UMR3347, Inserm U1021, Signalisation Radiobiologie et Cancer, Orsay, France.

Background: Proton minibeam radiation therapy (pMBRT) is a new radiotherapy approach that has shown a significant increase in the therapeutic window in glioma-bearing rats compared to conventional proton therapy. Such preclinical results encourage the preparation of clinical trials.

Purpose: In this study, the potential of pMBRT for treating clinical indications candidates for the first clinical trials (i.

View Article and Find Full Text PDF

Proton FLASH Radiation Therapy and Immune Infiltration: Evaluation in an Orthotopic Glioma Rat Model.

Int J Radiat Oncol Biol Phys

July 2023

Institut Curie, Université PSL, CNRS UMR3347, Inserm U1021, Signalisation Radiobiologie et Cancer, 91400 Orsay, France.

Article Synopsis
  • FLASH radiation therapy (FLASH-RT) utilizes ultrahigh doses of radiation to enhance treatment safety by protecting normal tissues while controlling tumor growth similarly to traditional radiation methods.
  • In a rat model of glioma, researchers compared high-dose FLASH proton therapy to conventional proton therapy, analyzing immune responses and protective effects.
  • The results indicated that FLASH-RT reduced memory impairment associated with high doses and triggered a comparable immune response in tumors, suggesting its potential as a safer treatment option.
View Article and Find Full Text PDF

First experimental measurements of 2D microdosimetry maps in proton therapy.

Med Phys

January 2023

Departamento de Física de Partículas, Universidad de Santiago de Compostela, Santiago de Compostela, Spain.

Background: Empirical data in proton therapy indicate that relative biological effectiveness (RBE) is not constant, and it is directly related to the linear energy transfer (LET). The experimental assessment of LET with high resolution would be a powerful tool for minimizing the LET hot spots in intensity-modulated proton therapy, RBE- or LET-guided evaluation and optimization to achieve biologically optimized proton plans, verifying the theoretical predictions of variable proton RBE models, and so on. This could impact clinical outcomes by reducing toxicities in organs at risk.

View Article and Find Full Text PDF

Preclinical dosimetry in proton minibeam radiation therapy: Robustness analysis and guidelines.

Med Phys

August 2022

Institut Curie, Université PSL, CNRS UMR3347, Inserm U1021, Signalisation Radiobiologie et Cancer, Orsay, France.

Purpose: Proton minibeam radiation therapy (pMBRT) is a new radiotherapy approach that has shown a significant increase in the therapeutic window in glioma-bearing rats compared to conventional proton therapy. The dosimetry of pMBRT is challenging and error prone due to the submillimetric beamlet sizes used. The aim of this study was to perform a robustness analysis on the setup parameters utilized in current preclinical trials and provide guidelines for reproducible dosimetry.

View Article and Find Full Text PDF

The European Particle Therapy Network (EPTN) consensus on the follow-up of adult patients with brain and skull base tumours treated with photon or proton irradiation.

Radiother Oncol

March 2022

KU Leuven, University of Leuven, Department of Oncology, Laboratory of Experimental Radiotherapy, Belgium; University Hospitals Leuven, Department of Radiation Oncology, Belgium; Particle Therapy Interuniversitary Center Leuven (PartICLe), Belgium; Leuven Kanker Instituut (LKI), UZ Leuven Gasthuisberg, Belgium.

Purpose: Treatment-related toxicity after irradiation of brain tumours has been underreported in the literature. Furthermore, there is considerable heterogeneity on how and when toxicity is evaluated. The aim of this European Particle Network (EPTN) collaborative project is to develop recommendations for uniform follow-up and toxicity scoring of adult brain tumour patients treated with radiotherapy.

View Article and Find Full Text PDF

Proton Minibeam Radiation Therapy and Arc Therapy: Proof of Concept of a Winning Alliance.

Cancers (Basel)

December 2021

Institut Curie, Université PSL, CNRS UMR3347, Inserm U1021, Signalisation Radiobiologie et Cancer, 91400 Orsay, France.

(1) Background: Proton Arc Therapy and Proton Minibeam Radiation Therapy are two novel therapeutic approaches with the potential to lower the normal tissue complication probability, widening the therapeutic window for radioresistant tumors. While the benefits of both modalities have been individually evaluated, their combination and its potential advantages are being assessed in this proof-of-concept study for the first time. (2) Methods: Monte Carlo simulations were employed to evaluate the dose and LET distributions in brain tumor irradiations.

View Article and Find Full Text PDF

Converging Proton Minibeams with Magnetic Fields for Optimized Radiation Therapy: A Proof of Concept.

Cancers (Basel)

December 2021

Centre de Protonthérapie d'Orsay, Department of Radiation Oncology, Institut Curie, Campus Universitaire, PSL Research University, 91898 Orsay, France.

Proton MiniBeam Radiation Therapy (pMBRT) is a novel strategy that combines the benefits of minibeam radiation therapy with the more precise ballistics of protons to further optimize the dose distribution and reduce radiation side effects. The aim of this study is to investigate possible strategies to couple pMBRT with dipole magnetic fields to generate a converging minibeam pattern and increase the center-to-center distance between minibeams. Magnetic field optimization was performed so as to obtain the same transverse dose profile at the Bragg peak position as in a reference configuration with no magnetic field.

View Article and Find Full Text PDF

Back to the Future: Very High-Energy Electrons (VHEEs) and Their Potential Application in Radiation Therapy.

Cancers (Basel)

September 2021

Centre de Protonthérapie d'Orsay, Department of Radiation Oncology, Campus Universitaire, Institut Curie, PSL Research University, 91898 Orsay, France.

The development of innovative approaches that would reduce the sensitivity of healthy tissues to irradiation while maintaining the efficacy of the treatment on the tumor is of crucial importance for the progress of the efficacy of radiotherapy. Recent methodological developments and innovations, such as scanned beams, ultra-high dose rates, and very high-energy electrons, which may be simultaneously available on new accelerators, would allow for possible radiobiological advantages of very short pulses of ultra-high dose rate (FLASH) therapy for radiation therapy to be considered. In particular, very high-energy electron (VHEE) radiotherapy, in the energy range of 100 to 250 MeV, first proposed in the 2000s, would be particularly interesting both from a ballistic and biological point of view for the establishment of this new type of irradiation technique.

View Article and Find Full Text PDF

First Evaluation of Temporal and Spatial Fractionation in Proton Minibeam Radiation Therapy of Glioma-Bearing Rats.

Cancers (Basel)

September 2021

Institut Curie, Université PSL, CNRS UMR3347, Inserm U1021, Signalisation Radiobiologie et Cancer, 91400 Orsay, France.

(1) Background: Proton minibeam radiation therapy (pMBRT) is a new radiotherapy technique using spatially modulated narrow proton beams. pMBRT results in a significantly reduced local tissue toxicity while maintaining or even increasing the tumor control efficacy as compared to conventional radiotherapy in small animal experiments. In all the experiments performed up to date in tumor bearing animals, the dose was delivered in one single fraction.

View Article and Find Full Text PDF

Conceptual Design of a Novel Nozzle Combined with a Clinical Proton Linac for Magnetically Focussed Minibeams.

Cancers (Basel)

September 2021

Institut Curie, Université Paris Saclay, CNRS UMR3347, Inserm U1021, Signalisation Radiobiologie et Cancer, 91400 Orsay, France.

(1) Background: Proton minibeam radiation therapy (pMBRT) is a novel therapeutic approach with the potential to significantly increase normal tissue sparing while providing tumour control equivalent or superior to standard proton therapy. For reasons of efficiency, flexibility and minibeam quality, the optimal implementation of pMBRT should use magnetically focussed minibeams which, however, could not yet be generated in a clinical environment. In this study, we evaluated our recently proposed minibeam nozzle together with a new clinical proton linac as a potential implementation.

View Article and Find Full Text PDF

Role of proton therapy in reirradiation and in the treatment of sarcomas.

Cancer Radiother

October 2021

Department of radiation oncology, Centre Antoine-Lacassagne, University of Côte d'Azur, 33, avenue de Valombrose, 06189 Nice, France.

Reirradiation and irradiation of sarcoma is often difficult due to the frequent need for a high dose of radiation in order to increase tumor control. This can result in a greater risk of toxicity which can be mitigated with the use of proton therapy. The present review aims to summarize the role of proton therapy in these 2 clinical contexts.

View Article and Find Full Text PDF

Future technological developments in proton therapy - A predicted technological breakthrough.

Cancer Radiother

October 2021

Institut Curie, PSL Research University, Radiation oncology department, Centre de protonthérapie d'Orsay, Campus universitaire, bâtiment 101, 91898 Orsay, France; Institut Curie, PSL Research University, University Paris Saclay, Inserm LITO, Campus universitaire, 91898 Orsay, France. Electronic address:

In the current spectrum of cancer treatments, despite high costs, a lack of robust evidence based on clinical outcomes or technical and radiobiological uncertainties, particle therapy and in particular proton therapy (PT) is rapidly growing. Despite proton therapy being more than fifty years old (first proposed by Wilson in 1946) and more than 220,000 patients having been treated with in 2020, many technological challenges remain and numerous new technical developments that must be integrated into existing systems. This article presents an overview of on-going technical developments and innovations that we felt were most important today, as well as those that have the potential to significantly shape the future of proton therapy.

View Article and Find Full Text PDF

[New indications of protontherapy for adults intracranial tumours].

Cancer Radiother

October 2021

Département de radiothérapie, centre François-Baclesse, Caen, France; Département de radiothérapie, CHU de Grenoble, Grenoble, France.

Considering intracranial tumours, only few indications of protontherapy, such as chordoma, chondrosarcoma or uveal melanoma, are uniformly approved in the world. Other indications, excluding paediatric pathologies, are still debated. The aim of this article is to describe the rationale for the use of protonbeam irradiation for meningioma, pituitary adenoma, craniopharyngioma, paraganglioma, glioma, and schwannoma, and to inform the radiation oncologists if prospective studies or randomized studies are opened for inclusions.

View Article and Find Full Text PDF

Update of the EPTN atlas for CT- and MR-based contouring in Neuro-Oncology.

Radiother Oncol

July 2021

Department of Radiotherapy and Radiation Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany; Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiooncology - OncoRay, Dresden, Germany; OncoRay - National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Helmholtz-Zentrum Dresden - Rossendorf Dresden, Germany; German Cancer Consortium (DKTK), partnersite Dresden and German Cancer Research Center (DKFZ), Germany; National Center for Tumor Diseases (NCT), Partner Site Dresden, Germany; German Cancer Research Center (DKFZ), Heidelberg, Germany; Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresde, Germany; Helmholtz Association / Helmholtz-Zentrum Dresden - Rossendorf (HZDR)., Germany.

Background And Purpose: To update the digital online atlas for organs at risk (OARs) delineation in neuro-oncology based on high-quality computed tomography (CT) and magnetic resonance (MR) imaging with new OARs.

Materials And Methods: In this planned update of the neurological contouring atlas published in 2018, ten new clinically relevant OARs were included, after thorough discussion between experienced neuro-radiation oncologists (RTOs) representing 30 European radiotherapy-oncology institutes. Inclusion was based on daily practice and research requirements.

View Article and Find Full Text PDF

 To investigate on the feasibility and safety of a new approach which consists of delaying instrumentation after destabilizing craniovertebral junction (CVJ) chordoma surgery, allowing proton beam radiotherapy to be performed in a metal-free tumoral cavity.  This is a retrospective series of a prospectively maintained database.  Five consecutive patients operated on for a CVJ chordomas for which instrumentation after tumor resection was deferred to after radiotherapy treatment.

View Article and Find Full Text PDF

UHDpulse - Metrology for advanced radiotherapy using particle beams with ultra-high pulse dose rates is a recently started European Joint Research Project with the aim to develop and improve dosimetry standards for FLASH radiotherapy, very high energy electron (VHEE) radiotherapy and laser-driven medical accelerators. This paper gives a short overview about the current state of developments of radiotherapy with FLASH electrons and protons, very high energy electrons as well as laser-driven particles and the related challenges in dosimetry due to the ultra-high dose rate during the short radiation pulses. We summarize the objectives and plans of the UHDpulse project and present the 16 participating partners.

View Article and Find Full Text PDF

Proton minibeam radiation therapy (pMBRT) is a new approach in proton radiotherapy, by which a significant increase in the therapeutic index has already been demonstrated in RG2 glioma-bearing rats. In the current study we investigated the response of other types of glioma (F98) and performed a comparative evaluation of tumor control effectiveness by pMBRT (with different levels of dose heterogeneity) versus conventional proton therapy. The results of our study showed an equivalent increase in the lifespan for all evaluated groups (conventional proton irradiation and pMBRT) and no significant differences in the histopathological analysis of the tumors or remaining brain tissue.

View Article and Find Full Text PDF

Radiotherapy (RT) is one of the most frequently used methods for cancer treatment. Despite remarkable advancements in RT techniquesthe treatment of radioresistant tumours (i.e.

View Article and Find Full Text PDF

Prescription and delivery of protons are somewhat different compared to photons and may influence outcomes (tumour control and toxicity). These differences should be taken into account to fully exploit the clinical potential of proton therapy. Innovations in proton therapy treatment are also required to widen the therapeutic window and determine appropriate populations of patients that would benefit from new treatments.

View Article and Find Full Text PDF

A diamond guard ring microdosimeter for ion beam therapy.

Rev Sci Instrum

May 2020

CEA-LIST, Diamond Sensors Laboratory, 91191 Gif-sur-Yvette, France.

A single crystal chemical vapor deposition diamond-based microdosimeter prototype featuring an array of micro-sensitive volumes (μSVs) and surrounded by a so-called guard ring (GR) electrode has been fabricated using various microfabrication techniques available at Diamond Sensors Laboratory of CEA, Saclay. The GR microdosimeter was irradiated by a raster scanning method with 2 MeV proton microbeams. The charge transport properties of the GR sensor were determined with sub-micron spatial resolution by measuring the charge collection efficiency (CCE), the μSV geometry, and the pulse-height spectra.

View Article and Find Full Text PDF